Sell Before the Cliff: A Business Development Playbook for Sterile Manufacturing Suppliers Targeting Biologic LOE
The hardest part of biologics isn’t the science—it’s the timing.
For sterile manufacturing suppliers, the “cliff” is loss of exclusivity (…
The patent clock is ticking. Drug companies are learning how to make it look like it isn’t.
For years, the public narrative around drug pricing has focused on one villain: the “generic delay.” But the real story is more technical—and more consequential…
Patients don’t ask “What’s the patent landscape?”—they ask, “Can I get my medicine cheaper, sooner, and without risking my health?”
That’s the real story behind the growing wave of online questions about drug switching. And it’s not just curiosity. It’…
Drug Switching Questions: What Patients Are Really Asking Online Read Post »
Evergreen strategies are getting smarter—and so do the teams trying to beat them.
For years, “brand” companies have used a familiar playbook: extend exclusivity not by inventing a cure, but by tightening the legal perimeter around an existing one. New …
GPT, Rosalind, and Generic Drugs: What OpenAI’s Life Sciences Model Actually Changes
The life sciences industry loves a good “breakthrough” story. But the real question isn’t whether AI can generate text, summarize papers, or even draft lab protocols. …
GPT-Rosalind and Generic Drugs: What OpenAI’s Life Sciences Model Actually Changes Read Post »
The patent cliff isn’t just a legal event. It’s a timing problem.
Most pharma teams treat patent expiry as a countdown—file the right paperwork, watch the litigation calendar, and hope the launch math still works. But the companies winning in the post-…
Beat the Patent Cliff: How to Trigger Payer Strategy Campaigns Before Drug Patent LOE Read Post »
OpenAI’s GPT just did something that should make every drug-patent strategist sit up: it “smashed” through some of the most stubborn cliffs in pharma IP—reportedly delivering answers up to 70x faster than traditional approaches. That’s not just a produ…
OpenAI’s GPT-Rosalind = Smashed Drug Patent Cliffs and 70% Faster ANDAs Read Post »
Predict the Attack: How to Forecast Paragraph IV Drug Patent Challenges and Neutralize “Skinny Label” Threats
If you’re in pharma strategy, legal, or commercial planning, you already know the uncomfortable truth: Paragraph IV challenges don’t arrive wi…
Your drug’s “patent life” isn’t one number—it’s a moving target across the GCC. Here’s how to know exactly how long you’re protected.
In the GCC, the question “How long does my drug patent last?” is often answered with a guess.
But in practice, the ans…
Know Exactly How Long Your Drug Patent Lasts in the GCC Read Post »
Unlocking the Hidden Timeline: How Long Do Drug Patents Last in the GCC?
Imagine investing millions into developing a groundbreaking medication, only to find out that your exclusive rights could expire sooner than expected, or worse, that your competit…
Know Exactly How Long Your Drug Patent Lasts in the GCC Read Post »
Get new actionable insights and updates from BiotechBlog
